Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Immune Design Corp. (IMDZ)
|
Add to portfolio |
|
|
|
| Price: |
$5.85
| | Metrics |
| OS: |
48.4
|
M
| |
-60
|
% ROE
|
| Market cap: |
$283
|
M
| |
-316
|
% ROIC
|
|
Net cash:
|
$95.9
|
M
| |
$1.98
|
per share
|
|
EV:
|
$187
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($56.7)
|
M
| |
|
|
|
EBIT
|
($57.1)
|
M
| |
|
|
| EPS |
($1.14)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 | Dec-31-12 |
| Revenues | 2.2 | 7.2 | 13.3 | 9.5 | 6.4 | 1.6 | 3.0 |
| Revenue growth | -69.5% | -45.7% | 39.4% | 47.8% | 302.3% | -46.0% | |
| Cost of goods sold | 1.4 | 0.1 | 0.5 | 0.8 | 0.6 | 0.7 | 1.5 |
| Gross profit | 0.8 | 7.1 | 12.8 | 8.7 | 5.8 | 0.9 | 1.4 |
| Gross margin | 34.7% | 98.8% | 96.4% | 91.9% | 90.1% | 58.2% | 48.7% |
| Research and development | 42.4 | 43.7 | 45.1 | 33.1 | 22.7 | 11.6 | 8.6 |
| General and administrative | 15.4 | 16.3 | 21.9 | 15.1 | 12.9 | 4.4 | 3.7 |
| EBIT | -57.1 | -52.8 | -54.2 | -39.5 | -29.9 | -15.1 | -10.9 |
| EBIT margin | -2597.9% | -734.0% | -408.9% | -415.2% | -464.4% | -941.7% | -367.4% |
| Pre-tax income | -54.8 | -51.9 | -53.5 | -39.4 | -34.2 | -16.0 | -10.8 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -54.8 | -51.9 | -53.5 | -39.4 | -34.2 | -16.0 | -10.8 |
| Net margin | -2493.5% | -720.8% | -403.7% | -414.8% | -530.9% | -999.1% | -366.2% |
| |
| Diluted EPS | ($1.14) | ($1.75) | ($2.47) | ($2.06) | ($4.56) | ($43.48) | ($30.43) |
| Shares outstanding (diluted) | 48.1 | 29.6 | 21.6 | 19.2 | 7.5 | 0.4 | 0.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|